Current Document Type: HighlightsVideoPage Elranatamab for Patients With Relapsed or Refractory Multiple Myeloma - JADPRO

Watch More Highlights

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses findings from the MagnetisMM-1 trial on elranatamab, a humanized bispecific molecule that targets BCMA expressed in multiple myeloma and engages CD3 on T cells. The results, of interest to advanced practitioners, support continued development of elranatamab as a single agent and in combination with standard treatments for patients with relapsed or refractory multiple myeloma (Abstract 895).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.